Online first
Review paper
Published online: 2024-11-05
Umbrella trials as a novel concept of cancer clinical trials — a systematic review
Abstract
Precision medicine in oncology is a strategy for selecting cancer patients with specific molecular disorders that may be suitable for targeted therapies at the cellular level. With the development of targeted therapies, pharmaceutical companies emphasize the importance of molecular clinical trials in oncology. Umbrella trials are prospective clinical trials that test multiple targeted therapeutic options against specific molecular targets in a single disease entity. In contrast, basket trials recruit patients with different cancers but at the same molecular level. The development of umbrella and basket trials not only reduces the costs of clinical trials but also provides patients with access to modern experimental therapies.
This article aims to present the principles of conducting umbrella and basket studies and present currently ongoing experiments in patients with the most common cancers. The development of oncology requires physicians to follow new developments in diagnostics and therapy, which may directly improve the prognosis of our patients. An individual approach to the patient is the future of precision oncology.
Keywords: umbrella trialscancercancer clinical trials
References
- Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. The National Academies Press, Washington DC 2011.
- Rubin MA. Health: Make precision medicine work for cancer care. Nature. 2015; 520(7547): 290–291.
- König IR, Fuchs O, Hansen G, et al. What is precision medicine? Eur Respir J. 2017; 50(4).
- Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol. 2018; 36(1): 46–60.
- Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015; 313(21): 2119–2120.
- FDA. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and (28.12.2023).
- Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019; 20(1): 572.
- Fountzilas E, Tsimberidou AM, Vo HH, et al. Clinical trial design in the era of precision medicine. Genome Med. 2022; 14(1): 101.
- Redman MW, Allegra CJ. The Master Protocol Concept. Semin Oncol. 2015; 42(5): 724–730.
- Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017; 377(1): 62–70.
- Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10): 883–892.
- Kwak EL, Sordella R, Bell DW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21): 2129–2139.
- Page M, McKenzie J, Bossuyt P, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021: n71.
- Bergethon K, Shaw AT, Ou SHI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8): 863–870.
- Middleton G, Fletcher P, Popat S, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020; 583(7818): 807–812; Erratum in: Nature. 2020; 585(7826): E21.
- Maggie Liu SY, Dong XR, Wang Z, et al. Efficacy, safety and dose selection of AZD3759 in patients with untreated -mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. EClinicalMedicine. 2023; 64: 102238.
- Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011; 1(1): 44–53.
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417): 519–525; Erratum in: Nature. 2012; 491(7423): 288.
- Aggarwal C, Redman MW, Lara PN, et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019; 14(10): 1847–1852.
- Park S, Shim J, Jung H, et al. Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer. J Clin Oncol. 2019; 37(15_suppl): 8514–8514.
- Greenwalt I, Zaza N, Das S, et al. Precision Medicine and Targeted Therapies in Breast Cancer. Surg Oncol Clin N Am. 2020; 29(1): 51–62.
- Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019; 321(3): 288–300.
- Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015; 21(7): 1688–1698.
- Wu SY, Wang H, Shao ZM, et al. Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Sci China Life Sci. 2021; 64(3): 372–388.
- Nitz UA, Gluz O, Graeser M, et al. WSG-ADAPT investigators. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022; 23(5): 625–635.
- Zambetti M, Montemurro F, Morandi P, et al. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. Eur J Cancer. 2018; 105: 61–70.
- Jiang YZ, Liu Y, Xiao Yi, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021; 31(2): 178–186.
- Liu Y, Zhu XZ, Xiao Yi, et al. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Res. 2023; 33(5): 389–402.
- Stanford University database. Umbrella Trial Testing Integrative Subtype- Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer. https://clinicaltrials.stanford.edu/trials/u/NCT05101564.html (28.11.2023).
- Chen C, Lin CJ, Pei YC, et al. Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell Discov. 2023; 9(1): 125.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424; Erratum in: CA Cancer J Clin. 2020; 70(4): 313.
- Lee CK, Kim HS, Jung M, et al. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. J Clin Oncol. 2024; 42(3): 348–357.
- Hospices Civil de Lyon. Clinicaltrials.gov database. Personalized Targeted IMMUNOtherapy- based Regimens in Recurrent GASTric Adenocarcinoma (IMMU- NOGAST) (IMMUNOGAST). https://clinicaltrials.gov/study/NCT04739202?cond=NCT04739202&rank=1 (28.11.2023).
- Yonsei University. Clinicaltrials.gov database, Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial. https://clinicaltrials.gov/study/NCT05270889 (28.12.2023).
- Ko AH, Kim KP, Siveke JT, et al. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023; 28(6): 553–e472.
- American Cancer Society. Key Statistics for Ovarian Cancer. 2023. https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html (28.12.2023).
- Morand S, Devanaboyina M, Staats H, et al. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci. 2021; 22(12).
- Mirza M, Henriksen JR, Maenpaa J, et al. 1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC). Int J Gynecol Cancer. 2021: A376.2–A376.
- Lee JY, Kim BG, Kim JW, et al. Korean Gynecologic Oncology Group (KGOG) investigators. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. J Gynecol Oncol. 2022; 33(4): e45.
- WHO. Cervial Cancer Key statistic. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer (28.12.2023).
- Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). Int J Gynecol Cancer. 2020; 30(1): 139–143.
- Italiano A, Dinart D, Soubeyran I, et al. MULTISARC study group. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. BMC Cancer. 2021; 21(1): 1180.
- Ko AH, Kim KP, Siveke JT, et al. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023; 28(6): 553–e472.
- Wick W, Dettmer S, Berberich A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019; 21(1): 95–105.
- Keam B, Hong MH, Shin SH, et al. KCSG TRIUMPH Investigators. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial. J Clin Oncol. 2024; 42(5): 507–517.
- Sun Yat-sen University, Clinicaltrials.gov database. EPstein-barr Virus DNA Response to Sys- temic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) (EP-STAR). https://clinicaltrials.gov/study/NCT04072107 (28.12.2023).
- Cancer Research UK, Clinicaltrials.gov database. DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly De- fined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE). https://clinicaltrials.gov/study/NCT05722886 (28.12.2023).
- Cancer Research UK, Clinicaltrials.gov database. DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE). https://clinicaltrials.gov/study/NCT05768178?cond=NCT05768178&rank=1 (28.12.2023).
- King NM. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics. 2000; 28(4): 332–343.
- Strzebonska K, Blukacz M, Wasylewski MT, et al. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Med. 2022; 20(1): 219.